FREE Shipping over 150 AED. Cash On Delivery (COD) Available in UAE ! Delivery within 3 Working Days!
100% Authentic Product. Double Cash Reward If proven Otherwise!
Hurry up! Sale Ends indayshoursminssecs
ROGAINE® Extra Strength Solution is a colorless liquid medication containing 5% minoxidil for use only on the scalp to help regrow hair in men.
Who may use Men’s ROGAINE®
Extra Strength Solution?
ROGAINE® Extra Strength Solution is for use only by men. ROGAINE® Extra Strength Solution
may be appropriate for you if you are a male at least 18 years old and experiencing gradually
thinning hair or gradual hair loss on the top of the scalp (vertex only, as shown on the next page). It is not intended for frontal baldness or a receding hairline. The common inherited thinning or hair loss process begins slowly and may become noticeable only after years of gradual loss.
ROGAINE® Extra Strength Solution is for men with hair loss or thinning hair that begins on the vertex of the scalp. ROGAINE® Extra Strength Solution is more likely to regrow hair in men with hair loss in the range shown on the next page. If men have more hair loss than shown, ROGAINE® Extra Strength may not work.
Help hair loss and regrow fuller hair with Men’s Rogaine Extra Strength 5% Minoxidil Topical Solution. Ideal for use at the early stages of hair thinning, this hair regrowth treatment is clinically proven to regrow hair. Unlike hair loss shampoos and hair thickening products that temporarily plump hair from the outside, Rogaine penetrates the scalp to reactivate shrunken hair follicles, allowing for regrowth of hair. The extra strength 5% Minoxidil formula works to boost hair follicle activity and hair protein production, helping to maintain hair density. This hair thinning treatment comes in a topical solution that is easy to use: simply apply 1 milliliter directly to your scalp twice daily and massage it through your hair. Like all Rogaine products, it is designed to fit easily into your routine. Based on hair count among men and women in clinical studies performed for FDA approval, Jan 2006.